VEGF Signalling - Life Sciences bibliographies - in Harvard style

In-text: (Banks, 2006)

Your Bibliography: Banks, R., 2006. Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer. Cancer Research, 66(4), pp.2000-2011.

In-text: (Bluyssen et al., 2004)

Your Bibliography: Bluyssen, H., Lolkema, M., van Beest, M., Boone, M., Snijckers, C., Los, M., Gebbink, M., Braam, B., Holstege, F., Giles, R. and Voest, E., 2004. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Letters, 556(1-3), pp.137-142.

In-text: (Bonicalzi, Groulx, de Paulsen and Lee, 2000)

Your Bibliography: Bonicalzi, M., Groulx, I., de Paulsen, N. and Lee, S., 2000. Role of Exon 2-encoded  -Domain of the von Hippel-Lindau Tumor Suppressor Protein. Journal of Biological Chemistry, 276(2), pp.1407-1416.

In-text: (Brahimi-Horn, Mazure and Pouysségur, 2005)

Your Bibliography: Brahimi-Horn, C., Mazure, N. and Pouysségur, J., 2005. Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cellular Signalling, 17(1), pp.1-9.

In-text: (Von Hippel-Lindau Syndrome, 2012)

Your Bibliography: Cancer.Net. 2012. Von Hippel-Lindau Syndrome. [online] Available at: <http://www.cancer.net/cancer-types/von-hippel-lindau-syndrome> [Accessed 26 February 2015].

In-text: (Cancer Stats: Cancer Statistics for the UK : Cancer Research UK, 2015)

Your Bibliography: Cancerresearchuk.org. 2015. Cancer Stats: Cancer Statistics for the UK : Cancer Research UK. [online] Available at: <http://www.cancerresearchuk.org/cancer-info/cancerstats/> [Accessed 26 February 2015].

In-text: (Chen et al., 1995)

Your Bibliography: Chen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., Gnarra, J., Orcutt, M., Duh, F., Glenn, G., Green, J., Hsia, Y., Lamiell, J., Li, H., Wei, M., Schmidt, L., Tory, K., Kuzmin, I., Stackhouse, T., Latif, F., Linehan, W., Lerman, M. and Zbar, B., 1995. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum. Mutat., 5(1), pp.66-75.

In-text: (Cooke, 2002)

Your Bibliography: Cooke, J., 2002. Nitric Oxide and Angiogenesis. Circulation, 105(18), pp.2133-2135.

In-text: (Cowey and Rathmell, 2009)

Your Bibliography: Cowey, C. and Rathmell, W., 2009. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports, 11(2), pp.94-101.

In-text: (Dandanell et al., 2012)

Your Bibliography: Dandanell, M., Friis-Hansen, L., Sunde, L., Nielsen, F. and Hansen, T., 2012. Identification of 3 novel VHL germ-line mutations in Danish VHL patients. BMC Med Genet, 13(1), p.54.

In-text: (Duan et al., 1995)

Your Bibliography: Duan, D., Pause, A., Burgess, W., Aso, T., Chen, D., Garrett, K., Conaway, R., Conaway, J., Linehan, W. and Klausner, R., 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science, 269(5229), pp.1402-1406.

In-text: (Ferrara, Gerber and LeCouter, 2003)

Your Bibliography: Ferrara, N., Gerber, H. and LeCouter, J., 2003. The biology of VEGF and its receptors. Nat Med, 9(6), pp.669-676.

In-text: (Foda and Zucker, 2001)

Your Bibliography: Foda, H. and Zucker, S., 2001. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discovery Today, 6(9), pp.478-482.

In-text: (KEGG PATHWAY: MAPK signaling pathway - Homo sapiens (human), 2015)

Your Bibliography: Genome.jp. 2015. KEGG PATHWAY: MAPK signaling pathway - Homo sapiens (human). [online] Available at: <http://www.genome.jp/kegg-bin/show_pathway?hsa04010> [Accessed 25 February 2015].

In-text: (Glenn et al., 1991)

Your Bibliography: Glenn, G., Daniel, L., Choyke, P., Linehan, W., Oldfield, E., Gorin, M., Hosoe, S., Latif, F., Weiss, G., Walther, M., Lerman, M. and Zbar, B., 1991. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Human Genetics, 87(2), pp.207-210.

In-text: (Harris, 2002)

Your Bibliography: Harris, A., 2002. HYPOXIA — A KEY REGULATORY FACTOR IN TUMOUR GROWTH. Nat. Rev. Cancer., 2(1), pp.38-47.

In-text: (Hewitson et al., 2002)

Your Bibliography: Hewitson, K., McNeill, L., Riordan, M., Tian, Y., Bullock, A., Welford, R., Elkins, J., Oldham, N., Bhattacharya, S., Gleadle, J., Ratcliffe, P., Pugh, C. and Schofield, C., 2002. Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family. Journal of Biological Chemistry, 277(29), pp.26351-26355.

In-text: (Hickman, 1996)

Your Bibliography: Hickman, J., 1996. Apoptosis and chemotherapy resistance. European Journal of Cancer, 32(6), pp.921-926.

In-text: (Hoeben, 2004)

Your Bibliography: Hoeben, A., 2004. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacological Reviews, 56(4), pp.549-580.

In-text: (Jewell, 2001)

Your Bibliography: Jewell, U., 2001. Induction of HIF-1a in response to hypoxia is instantaneous. The FASEB Journal,.

In-text: (Kaelin and Maher, 1998)

Your Bibliography: Kaelin, W. and Maher, E., 1998. The VHL tumour-suppressor gene paradigm. Trends in Genetics, 14(10), pp.423-426.

In-text: (Kaelin, 2002)

Your Bibliography: Kaelin, W., 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer., 2(9), pp.673-682.

In-text: (Kaelin et al., 2000)

Your Bibliography: Kaelin, W., Ohh, M., Park, C., Ivan, M., Hoffman, M., Kim, T., Huang, L., Pavletich, N. and Chau, V., 2000. Nature Cell Biology, 2(7), pp.423-427.

In-text: (Kamura, 1999)

Your Bibliography: Kamura, T., 1999. Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase. Science, 284(5414), pp.657-661.

In-text: (Keith, Johnson and Simon, 2011)

Your Bibliography: Keith, B., Johnson, R. and Simon, M., 2011. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer,.

In-text: (Kibel, Iliopoulos, DeCaprio and Kaelin, 1995)

Your Bibliography: Kibel, A., Iliopoulos, O., DeCaprio, J. and Kaelin, W., 1995. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science, 269(5229), pp.1444-1446.

In-text: (Li, 2003)

Your Bibliography: Li, Z., 2003. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. The EMBO Journal, 22(8), pp.1857-1867.

In-text: (Liakopoulos et al., 1999)

Your Bibliography: Liakopoulos, D., Busgen, T., Brychzy, A., Jentsch, S. and Pause, A., 1999. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proceedings of the National Academy of Sciences, 96(10), pp.5510-5515.

In-text: (Mac Gabhann and Popel, 2007)

Your Bibliography: Mac Gabhann, F. and Popel, A., 2007. Dimerization of VEGF receptors and implications for signal transduction: A computational study. Biophysical Chemistry, 128(2-3), pp.125-139.

In-text: (Key statistics - Macmillan Cancer Support, 2015)

Your Bibliography: Macmillan.org.uk. 2015. Key statistics - Macmillan Cancer Support. [online] Available at: <http://www.macmillan.org.uk/Aboutus/Ouresearchandevaluation/Researchandevaluation/Keystatistics.aspx> [Accessed 26 February 2015].

In-text: (MAHER et al., 1990)

Your Bibliography: MAHER, E., YATES, J., HARRIES, R., BENJAMIN, C., HARRIS, R., MOORE, A. and FERGUSON-SMITH, M., 1990. Clinical Features and Natural History of von Hippel-Lindau Disease. QJM, 77(2), pp.1151-1163.

In-text: (Masson et al., 2001)

Your Bibliography: Masson, N., Willam, C., Maxwell, P., Pugh, C. and Ratcliffe, P., 2001. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. The EMBO Journal, 20(18), pp.5197-5206.

In-text: (Cancer Definition - Diseases and Conditions - Mayo Clinic, 2015)

Your Bibliography: Mayoclinic.org. 2015. Cancer Definition - Diseases and Conditions - Mayo Clinic. [online] Available at: <http://www.mayoclinic.org/diseases-conditions/cancer/basics/definition/con-20032378> [Accessed 25 February 2015].

In-text: (Pheochromocytoma Definition - Diseases and Conditions - Mayo Clinic, 2015)

Your Bibliography: Mayoclinic.org. 2015. Pheochromocytoma Definition - Diseases and Conditions - Mayo Clinic. [online] Available at: <http://www.mayoclinic.org/diseases-conditions/pheochromocytoma/basics/definition/con-20030435> [Accessed 26 February 2015].

In-text: (Ohh et al., 1998)

Your Bibliography: Ohh, M., Yauch, R., Lonergan, K., Whaley, J., Stemmer-Rachamimov, A., Louis, D., Gavin, B., Kley, N., Kaelin, W. and Iliopoulos, O., 1998. The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix. Molecular Cell, 1(7), pp.959-968.

In-text: (Richard et al., 1999)

Your Bibliography: Richard, D., Berra, E., Gothie, E., Roux, D. and Pouyssegur, J., 1999. p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1  (HIF-1 ) and Enhance the Transcriptional Activity of HIF-1. Journal of Biological Chemistry, 274(46), pp.32631-32637.

In-text: (Richards, 1996)

Your Bibliography: Richards, F., 1996. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Human Molecular Genetics, 5(5), pp.639-644.

In-text: (Rowbotham et al., 2014)

Your Bibliography: Rowbotham, D., Enfield, K., Martinez, V., Thu, K., Vucic, E., Stewart, G., Bennewith, K. and Lam, W., 2014. Multiple Components of the VHL Tumor Suppressor Complex Are Frequently Affected by DNA Copy Number Loss in Pheochromocytoma. International Journal of Endocrinology, 2014, pp.1-9.

In-text: (Schauer, 2000)

Your Bibliography: Schauer, A., 2000. Book review: Apoptosis and Cancer Chemotherapy. Bioessays, 22(6), pp.592-592.

In-text: (Schoenfeld, Davidowitz and Burk, 1998)

Your Bibliography: Schoenfeld, A., Davidowitz, E. and Burk, R., 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proceedings of the National Academy of Sciences, 95(15), pp.8817-8822.

In-text: (Seizinger et al., 1988)

Your Bibliography: Seizinger, B., Rouleau, G., Ozelius, L., Lane, A., Farmer, G., Lamiell, J., Haines, J., Yuen, J., Collins, D., Majoor-Krakauer, D., Bonner, T., Mathew, C., Rubenstein, A., Halperin, J., McConkie-Rosell, A., Green, J., Trofatter, J., Ponder, B., Eierman, L., Bowmer, M., Schimke, R., Oostra, B., Aronin, N., Smith, D., Drabkin, H., Waziri, M., Hobbs, W., Martuza, R., Conneally, P., Hsia, Y. and Gusella, J., 1988. Von Hippel�Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature, 332(6161), pp.268-269.

In-text: (Stebbins, 1999)

Your Bibliography: Stebbins, C., 1999. Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function. Science, 284(5413), pp.455-461.

In-text: (Stebbins, 1999)

Your Bibliography: Stebbins, C., 1999. Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function. Science, 284(5413), pp.455-461.

In-text: (Sweeney and ; Griffing, 2015)

Your Bibliography: Sweeney, A. and ; Griffing, G., 2015. Pheochromocytoma. [online] Emedicine.medscape.com. Available at: <http://emedicine.medscape.com/article/124059-overview> [Accessed 26 February 2015].

In-text: (Talks et al., 2000)

Your Bibliography: Talks, K., Turley, H., Gatter, K., Maxwell, P., Pugh, C., Ratcliffe, P. and Harris, A., 2000. The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages. The American Journal of Pathology, 157(2), pp.411-421.

In-text: (Tanimoto, 2000)

Your Bibliography: Tanimoto, K., 2000. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. The EMBO Journal, 19(16), pp.4298-4309.

In-text: (Tomlinson, 2001)

Your Bibliography: Tomlinson, I., 2001. Two hits revisited again. Journal of Medical Genetics, 38(2), pp.81-85.

In-text: (Vaupel, 2004)

Your Bibliography: Vaupel, P., 2004. The Role of Hypoxia-Induced Factors in Tumor Progression. The Oncologist, 9(suppl_5), pp.10-17.

In-text: (Wang, Jiang, Rue and Semenza, 1995)

Your Bibliography: Wang, G., Jiang, B., Rue, E. and Semenza, G., 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences, 92(12), pp.5510-5514.

In-text: (Weidemann and Johnson, 2008)

Your Bibliography: Weidemann, A. and Johnson, R., 2008. Biology of HIF-1α. Cell Death and Differentiation, [online] 15, pp.621-627. Available at: <http://www.nature.com/cdd/journal/v15/n4/full/cdd200812a.html> [Accessed 25 February 2015].

In-text: (Woodward et al., 2000)

Your Bibliography: Woodward, E., Buchberger, A., Clifford, S., Hurst, L., Affara, N. and Maher, E., 2000. Comparative Sequence Analysis of the VHL Tumor Suppressor Gene. Genomics, 65(3), pp.253-265.

In-text: (Zbar et al., 1996)

Your Bibliography: Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E., Richards, F., Crossey, P., Webster, A., Affara, N., Ferguson‐Smith, M., Brauch, H., Glavac, D., Neumann, H., Tisherman, S., Mulvihill, J., Gross, D., Shuin, T., Whaley, J., Seizinger, B., Kley, N., Olschwang, S., Boisson, C., Richard, S., Lips, C., Linehan, W. and Lerman, M., 1996. Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat., 8(4), pp.348-357.